| |
Edited Excerpts from the 2005 ASTRO Meeting Satellite
|
|
| |
Click here to download the entire interview |
|
|
| Track 1 |
Introduction by Neil Love, MD |
 |
 |
| Track 2 |
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy |
|
|
| Track 3 |
Studies of radiation therapy dose for patients with clinically localized prostate cancer |
|
|
| Track 4 |
Randomized trial of six-month androgen suppression and radiation therapy versus radiation therapy
alone for patients with clinically localized prostate cancer |
|
|
| Track 5 |
Short-term androgen deprivation and radiation therapy for locally advanced prostate cancer |
|
|
| Track 6 |
Case discussion: A 61-year-old man with T1c Gleason 6 prostate cancer and a rapidly rising PSA |
|
|
| Track 7 |
Postoperative radiation therapy for patients at high risk for local recurrence |
|
|
| Track 8 |
Case discussion: A 53-year-old man with a rising PSA following surgery for Gleason 4 + 3 disease |
|
|
| Track 9 |
Postoperative adjuvant radiation therapy for patients with intermediate-grade prostate cancer |
|
|
| Track 10 |
Combined modality therapy for locally advanced prostate cancer |
|
|
| Track 11 |
Case discussion: A 74-year-old man with intermediate-risk prostate cancer and diabetes,
hypertension and hypercholesterolemia |
|
|
| Track 12 |
Case discussion: A 57-year-old man with Gleason 4 + 3 prostate cancer treated with brachytherapy |
|
|
| Track 13 |
Impact of supplemental external beam radiation on biochemical outcome after brachytherapy |
|
|
| Track 14 |
Androgen deprivation therapy in intermediate- and high-risk prostate cancer treated
with brachytherapy |
|
|
| Track 15 |
Determining the optimal timing for initiation of androgen deprivation therapy |
|
|
| Track 16 |
Immediate versus delayed postprostatectomy hormonal therapy |
|
|
| Track 17 |
Monotherapy versus combined androgen blockade |
|
|
| Track 18 |
Case discussion: A 62-year-old man with a slowly rising PSA and biopsy-confirmed prostate
cancer after brachytherapy for low-risk disease |
|
|
| Track 19 |
Salvage therapy for patients with recurrence after brachytherapy |
|
|
| Track 20 |
Selection of appropriate patients for salvage radiation therapy |
|
|
| Track 21 |
Case discussion: A 59-year-old man with Gleason 8 prostate cancer treated with radiation therapy
and hormonal therapy with a rapid PSA doubling time |
|
|
| Track 22 |
Use of docetaxel in patients with hormone-refractory disease |
|
|
| Track 23 |
Role of combined androgen blockade in the treatment of advanced prostate cancer |
|
|
| Track 24 |
Mechanism of action of anti-androgens |
|
|
| Track 25 |
Comparison of bicalutamide versus flutamide in combination with LHRH analogues |
|
|
| Track 26 |
Intermittent androgen deprivation therapy |
|
|
| Track 27 |
Bicalutamide monotherapy for patients with advanced prostate cancer |
|
|
| Track 28 |
Case discussion: A 60-year-old man with T1c Gleason 6 prostate cancer |
|
|
| Track 29 |
Watchful waiting versus active treatment for patients with low-risk disease |
|
|
| Track 30 |
Potential implications of positive trials of prostate cancer screening |
|
|
| |
|
|
|
 |
Interview with Anthony V D’Amico, MD, PhD
Professor and Chief of Genitourinary
Radiation Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Short-term androgen deprivation and radiation therapy for locally advanced prostate cancer |
|
|
| Track 3 |
Determining the optimal duration of hormonal therapy combined with radiation therapy |
|
|
| Track 4 |
Overdiagnosis of prostate cancer in the PSA era |
|
|
| Track 5 |
Preoperative PSA velocity and the risk of death from prostate cancer |
|
|
| Track 6 |
Staging and treatment for patients with Gleason 4 + 3 prostate cancer |
|
|
| Track 7 |
Radiation therapy for extracapsular extension, positive margins or seminal vesicle invasion
after prostatectomy |
|
|
| Track 8 |
Case discussion: A 62-year-old man with Gleason 8 prostate cancer and positive margins |
|
|
| Track 9 |
Genitourinary toxicity associated with radiation therapy after radical prostatectomy |
|
|
| Track 10 |
Case discussion: A 54-year-old man with T3a Gleason 8 prostate cancer |
|
|
| Track 11 |
High-dose bicalutamide and radiation therapy for patients with high-risk disease |
|
|
| Track 12 |
Case discussion: A 54-year-old man with T2a Gleason 3 + 4 prostate cancer |
|
|
| Track 13 |
Brachytherapy with or without external beam radiation or hormonal therapy for intermediate-risk disease |
|
|
| Track 14 |
Importance of brachytherapy dose coverage of the prostate for durable biochemical control |
|
|
| Track 15 |
Case discussion: A 58-year-old man with Gleason 8 disease and seminal vesicle involvement |
|
|
| Track 16 |
Impact of age on selection of adjuvant radiation therapy and hormonal therapy |
|
|
| Track 17 |
Duration of hormonal therapy for patients with high-risk disease |
|
|
| Track 18 |
Hormonal therapy with high-dose radiation therapy for patients with high-risk disease |
|
|
| Track 19 |
PSA doubling time and the time to development of positive bone scans |
|
|
| Track 20 |
Duration and schedule of hormonal therapy for patients with rising PSAs |
|
|
| Track 21 |
Six-month androgen suppression and radiation therapy with or without docetaxel for patients
with high-risk localized or locally advanced prostate cancer |
|
|
